SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients

Abdullah Algaissi[1,2,3,#], Mohamed A Alfaleh[1,4,#], Sharif Hala[5,6,#], Turki S Abujamel[1,7], Sawsan S Alamri[1,8], Sarah A Almahboub[1], Khalid A Alluhaybi[1,4], Haya I Hobani[1], Reem M Alsulaiman[1], Rahaf H AlHarbi[1,9], M-Zaki ElAssouli[1], Rowa Y Alhabbab[1,7], Ahdab A AlSaieedi[1,7], Wesam H Abdulaal[8], Afrah A AL-Somali[10], Fadwa S Alofi[11], Asim A Khogeer[12], Almohanad A Alkayyal[13], Ahmad Bakur Mahmoud[14], Naif AM Almontashiri[15], Arnab Pain[5,16,17], Anwar M Hashem[1,18,*]

[1] Vaccines and Immunotherapy Unit, King Fahd Medical Research Center; King Abdulaziz University, Jeddah, Saudi Arabia

[2] Department of Medical Laboratories Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia

[3] Medical Research Center, Jazan University, Jazan, Saudi Arabia

[4] Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia

[5] Pathogen Genomics Laboratory, Division of Biological and Environmental Sciences and Engineering (BESE), Thuwal, Saudi Arabia

[6] King Abdullah International Medical Research Centre, King Saud University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia

[7] Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia

[8] Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia

9 Department of Biology, faculty of science, King Abdulaziz university, Jeddah , Saudi Arabia

10 Infectious Diseases Department, King Abdullah medical complex, Jeddah, Saudi Arabia

11 Infectious Diseases Department, King Fahad Hospital, Almadinah Almunwarah, Saudi Arabia

12 Plan and Research Department, General Directorate of Health Affairs Makkah Region, Ministry of Health, Makkah, Saudi Arabia

13 Department of Medical Laboratory Technology, University of Tabuk, Tabuk, Saudi Arabia

14 College of Applied Medical Sciences, Taibah University, Almadinah Almunwarah, Saudi Arabia

15 Center for Genetics and Inherited Diseases, Taibah University, Almadinah Almunwarah, Saudi Arabia

16 Research Center for Zoonosis Control, Hokkaido University, N20 W10 Kita-ku, Sapporo, Japan

17 Nuffield Division of Clinical Laboratory Sciences (NDCLS), University of Oxford, Oxford, OX3 9DU, UK

18 Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

# equal contribution

* **Corresponding author:** Anwar M Hashem; Faculty of Medicine and King Fahd Medical Research Center, King Abdulaziz University, P.O.Box 80205, Jeddah 21859, Saudi Arabia. Tel. +966 (12) 6400000 ext. 21033, E-mail: amhashem@kau.edu.sa.

Key words: SARS-CoV-2; COVID-19; ELISA, Antibodies; Serology

Running title: ELISAs for COVID-19 antibodies testing

Supplementary Table 1. Area under the ROC curve (AUC) for the different developed ELISAs based on sample time collection.

ELISA	Samples	AUC ± SD	95% CI	P value
S1 IgG	All samples	0.940 ± 0.024	0.892 - 0.986	<0.0001
	Week 1 samples	0.746 ± 0.091	0.567 - 0.925	0.0099
	Week 2 samples	0.973 ± 0.020	0.935 - 1.000	<0.0001
	Week 3 samples	1.000 ± 0.000	1.000 - 1.000	<0.0001
	Week 4 samples	1.000 ± 0.000	1.000 - 1.000	0.0002
S1 IgM	All samples	0.963 ± 0.014	0.935 - 0.990	<0.0001
	Week 1 samples	0.829 ± 0.052	0.727 - 0.931	0.0006
	Week 2 samples	0.990 ± 0.007	0.977 - 1.000	<0.0001
	Week 3 samples	1.000 ± 0.000	1.000 - 1.000	<0.0001
	Week 4 samples	1.000 ± 0.000	1.00 0 -1.000	0.0002
N IgG	All samples	0.971 ± 0.015	0.942 - 1.000	<0.0001
	Week 1 samples	0.863 ± 0.065	0.736 - 0.990	0.0001
	Week 2 samples	0.994 ± 0.005	0.985 - 1.000	<0.0001
	Week 3 samples	1.000 ± 0.000	1.000 - 1.000	<0.0001
	Week 4 samples	1.000 ± 0.000	1.000 - 1.000	0.0002
N IgM	All samples	0.871 ± 0.035	0.803 - 0.940	<0.0001
	Week 1 samples	0.528 ± 0.111	0.311 - 0.746	0.7655
	Week 2 samples	0.982 ± 0.009	0.965 - 1.000	<0.0001
	Week 3 samples	0.929 ± 0.038	0.854 - 1.000	<0.0001
	Week 4 samples	0.884 ± 0.067	0.753 - 1.000	0.0037



Supplementary Figure 1. checkerboard titration to determine the optimium antigen concentration and dilution of serum samples in the developed SARS-CoV-2 ELISAs